Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
News Oct 23, 2009
Evotec AG has announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim. The collaboration, which was initiated in August 2004, has up to now resulted in seven milestone payments.
The achievement of the current milestone has led to a payment to Evotec of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for Pre-Development studies in a cardiometabolic program.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are extremely pleased that we have achieved another milestone in our alliance with Boehringer Ingelheim. This is the second milestone that we have achieved in 2009 and further demonstrates the success of our collaboration. We are looking forward to continuing our collaboration into 2010 and beyond and achieving further milestones as we progress several projects towards the clinic.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE